文献速递前列腺癌

晚期黄体生成素释放激素激动剂给药对前列腺癌患者睾酮抑制的影响:美国临床数据分析

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
PubMed 文献 · J Urol · 2019-10-03

回顾性分析22860例接受LHRH激动剂治疗的前列腺癌患者,评估给药延迟对睾酮水平的影响及睾酮和PSA检测频率。结果显示84%注射延迟(按28天月定义),延迟时睾酮>50 ng/dl的比例更高(27% vs 4%),且仅13%注射进行了睾酮检测。

要点

  • 按28天月定义,84%的LHRH激动剂注射延迟。
  • 延迟给药时睾酮>50 ng/dl的比例显著高于准时给药(27% vs 4%)。
  • 仅13%的注射进行了睾酮检测,PSA检测率为83%。

核心结论

  • LHRH激动剂给药常晚于关键试验方案(84%),延迟给药与更高的睾酮水平相关,且睾酮检测不足导致高睾酮未被识别。

研究设计与样本

  • 回顾性分析22860例接受LHRH激动剂治疗的前列腺癌患者记录,采用28天月和扩展月两种定义评估延迟给药。

主要发现

  • 按28天月定义,84%注射延迟;按扩展月定义,27%注射延迟。
  • 延迟给药时睾酮>50 ng/dl的比例分别为15%(28天月)和27%(扩展月),准时给药为4%。
  • 延迟给药时睾酮>20 ng/dl的比例分别为31%(28天月)和43%(扩展月),准时给药为22%和21%。
  • 延迟给药时平均睾酮更高:49 ng/dl(28天月)和79 ng/dl(扩展月),准时给药均为21 ng/dl。
  • PSA检测在83%的注射中进行,睾酮检测仅13%。

临床怎么用

  • 临床应关注LHRH激动剂给药及时性,并加强睾酮监测以识别未达去势水平者。

局限性

  • 回顾性研究设计,未报告其他潜在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the timeliness of androgen deprivation therapy dosing, the impact of dosing nonadherence on testosterone, and the frequency of testosterone and prostate specific antigen testing in patients with prostate cancer. MATERIALS AND METHODS: We retrospectively analyzed the records of 22,860 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonists. Analyses were done using 2 definitions of month, including a 28-day month (late dosing after day 28, 84, 112 or 168) and an extended month (late after day 32, 97, 128 or 194) for 1, 3, 4 and 6-month formulations, respectively. The prevalence of late dosing, associated testosterone values, and the frequency of testosterone and prostate specific antigen testing were assessed. Statistical significance was assessed with the unpaired t-test. RESULTS: Of the injections 84% and 27% were late for the 28-day and extended month analyses, respectively. For the 28-day month 60% and 29% of injections were late by more than 1 and more than 2 weeks, respectively. Of testosterone values 4% were greater than 50 ng/dl for early/on time injections using both definitions, and 15% and 27% were greater than 50 ng/dl when late, and for the 28-day month and the extended month, respectively. For early/on time vs late injections 22% vs 31% of testosterone values were greater than 20 ng/dl for the 28-day month and 21% vs 43% for the extended month. Mean testosterone was higher when late (49 ng/dl for 28-day month, 79 ng/dl for extended month) vs early/on time (both 21 ng/dl). Of the injections prostate specific antigen measurements were performed in 83% and testosterone assessment was done in only 13%. CONCLUSIONS: Luteinizing hormone-releasing hormone agonists were frequently (84%) administered later than the schedules used in pivotal trials. Nearly half of the late testosterone values for the extended month were greater than 20 ng/dl and mean testosterone was almost double the castration level. Elevated testosterone remained unidentified with infrequent testing.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Twardowski PW, Concepcion RS, et al. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2019. PMID: 31580749. doi:10.1097/JU.0000000000000577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。